Trial Profile

An Open Label, Adaptive Design Evaluation, Crossover Study of the Safety, Pharmacokinetics and Pharmacodynamics of Various RECCE327 Intravenous Dose and Infusion Rate

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jun 2024 Results from the trial at the highest dose, 4,000mg, of R327 published in the Recce Pharmaceuticals Media Release
12 Jun 2024 According to a Recce Pharmaceuticals media release, an Independent Safety Committee will review and evaluate the comprehensive data from the 6-subject cohort, with preliminary results expected in the near weeks.
12 Jun 2024 According to a Recce Pharmaceuticals media release, dosing of an additional cohort has been completed. Six additional participants intravenously dosed with RECCE 327 (R327) at 4,000mg over 20 minutes-highest dosage to date in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com